<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737448</url>
  </required_header>
  <id_info>
    <org_study_id>MP-0614-001</org_study_id>
    <nct_id>NCT03737448</nct_id>
  </id_info>
  <brief_title>TRimetazidine for acUte on Chronic Liver Failure STudy</brief_title>
  <acronym>TRUST</acronym>
  <official_title>A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the pharmacokinetics (PK), tolerability, and safety of oral
      trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the PK, tolerability, and safety of oral trimetazidine administered to
      subjects with acute-on-chronic (ACLF) Grades 1 and 2 with liver failure and a range of renal
      function. Subjects will receive up to 60 mg/day for 28 days.

      Two groups of subjects will be enrolled:

      Group 1

        -  AD with serum creatinine ≥ 1 and &lt; 2 mg/dL, OR

        -  ACLF 1 with

             -  liver failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or

             -  liver failure and West Haven grade 1-2 hepatic encephalopathy, or

             -  coagulation failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or

             -  coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR

        -  ACLF 2 with

             -  liver failure and coagulation failure, or

             -  liver failure and West Haven grade 3-4 hepatic encephalopathy.

      Group 2

        -  ACLF 1 with renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), OR

        -  ACLF 2 with

             -  liver failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), or

             -  coagulation failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma pharmacokinetics</measure>
    <time_frame>28 days</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma pharmacokinetics</measure>
    <time_frame>28 days</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events [Safety and Tolerability]</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AD with serum creatinine ≥ 1 and &lt; 2 mg/dL, OR
ACLF 1 with
liver failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or
liver failure and West Haven grade 1-2 hepatic encephalopathy, or
coagulation failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or
coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR
ACLF 2 with
liver failure and coagulation failure, or
liver failure and West Haven grade 3-4 hepatic encephalopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACLF 1 with renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), OR
ACLF 2 with
liver failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), or
coagulation failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine</intervention_name>
    <description>Subjects with receive up to 60 mg daily</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 75 years, inclusive, at screening.

          2. Stable diagnosis of AD, ACLF Grade 1 or ACLF Grade 2 for no less than 2 days (as
             determined at the discretion of the investigator)*.

          3. Anticipated duration of hospital stay of at least 7 days.

          4. For Group 1:

               -  AD with SCr ≥ 1 and &lt; 2 mg/dL, OR

               -  ACLF 1 with

                    -  Tbil ≥ 12 mg/dL, SCr ≥ 1.5 and &lt; 2 mg/dl, and HE 0-2, or

                    -  Tbil ≥ 12 mg/dL, and SCr &lt; 1.5 mg/dL, and HE 1-2, or

                    -  INR ≥ 2.5, SCr ≥ 1.5 and &lt; 2 mg/dl, and HE 0-2, or

                    -  INR ≥ 2.5, SCr &lt; 1.5 mg/dL, and HE 1-2, OR

               -  ACLF 2 with

                    -  Tbil ≥ 12 mg/dL, INR ≥ 2.5, and SCr &lt; 2 mg/dL, or

                    -  Tbil ≥ 12 mg/dL, HE 3-4, and SCr &lt; 2 mg/dL

          5. For Group 2:

               -  ACLF 1 with SCr ≥ 2.0 and &lt; 3.5 mg/dL, OR

               -  ACLF 2 with

                    -  Tbil ≥ 12 mg/dL, and SCr ≥ 2 and &lt; 3.5 mg/dL, or

                    -  INR ≥ 2.5, and SCr ≥ 2 and &lt; 3.5 mg/dL.

          6. Female patients must be of non-childbearing potential, or, if non-sterile, must agree
             to sexual abstinence or use a highly effective method of contraception from Screening
             to 3 days after the final dose.

          7. Non sterile male patients must agree to sexual abstinence or use a highly effective
             method of contraception from Screening to 3 days after the final dose if sexually
             active.

          8. Able to comprehend and willing to sign an informed consent form, or, if unable to
             consent, consent is conducted per local requirements.

        Exclusion Criteria:

          1. Diagnosis of AD or ACLF (of any grade) &gt;14 days before enrollment*.

          2. Circulatory failure.

          3. Respiratory failure i.e. PaO2/FiO2 ≤ 200 and/or baseline SpO2/FiO2 ≤ 214.

          4. Brain failure (West Haven grade 3 or 4 hepatic encephalopathy) with coagulation
             failure (INR &gt; 2.5).

          5. Gastrointestinal bleeding within 72 hours prior to enrollment. (Subjects who fail this
             criterion may qualify after 72 hours).

          6. Uncontrolled bacterial infection (urinary tract infection, spontaneous bacterial
             peritonitis, pneumonia, bacteremia, soft tissue infections, etc.) (as determined at
             the discretion of the investigator).

          7. Invasive fungal infection.

          8. Platelet count &lt;30,000 cells/mL.

          9. White blood cell count &lt;1000 cells/uL.

         10. Patients on hemodialysis or continuous venovenous hemofiltration.

         11. Patients who have undergone or are scheduled for imminent organ transplantation.
             (Patients may be on a transplant list as long as no date has been set for
             transplantation)

         12. Hospitalization for ACLF within the 3 months prior to screening.

         13. History of hepatocellular carcinoma, unless within Milan Criteria (up to 3 lesions
             each &lt; 3 cm or 1 lesion &lt; 5 cm; no extrahepatic involvement; no evidence of gross
             vascular invasion).

         14. Active non-hepatic malignancy.

         15. Parkinson's disease, Parkinsonian-type symptoms (gait disorder, tremor, etc.),
             restless leg syndrome or other movement disorders other than asterixis.

         16. Fulminant Wilson's, fulminant autoimmune hepatitis, or Budd-Chiari syndrome.

         17. Septic shock (hypotension requiring vasopressors to maintain a mean arterial pressure
             of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L (&gt; 18
             mg/dL) after adequate fluid resuscitation.

         18. Patients who have undergone placement of a transjugular intrahepatic portosystemic
             shunt (TIPS) or surgical shunt in the past 6 months.

         19. Any invasive procedure within 48 hours prior to enrollment with high risk of
             uncontrolled bleeding (as determined at the discretion of the investigator).

         20. Female with a positive pregnancy test or lactating.

         21. Positive results for human immunodeficiency virus HIV-1 or HIV-2.

         22. Current treatment with trimetazidine.

         23. Known allergy to trimetazidine or excipients.

         24. Currently receiving an investigational treatment.

         25. Any condition that, in the opinion of the Investigator (or designee), would limit the
             subject's ability to complete or participate in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Martin Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann C. Tunstall, PhD</last_name>
    <phone>7039818338</phone>
    <email>ann@martinpharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Stauber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Zoller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Reiberger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Francque, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Gustot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillippe Mathurin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Thabut, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludivine Legros, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faouzi Saliba, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Lange, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JW Goethe Clinic</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonel Trebicka, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Zipprich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Cornberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Heinz Weiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Berg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentin Fuhrmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Gines, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Valle de Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Genesca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel de la Mata, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Bañares, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Caleja, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Albillos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla Santander</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Ignacio Fortea, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Ampuero, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

